CureDuchenne, a nonprofit that raises awareness and funds research to find a cure for Duchenne muscular dystrophy, will host its first Blingo to CureDuchenne event on May 3 at the Hyatt Regency in Philadelphia. Blingo is an elegant evening of bingo and bling with celebrity guests to raise funds to find a cure for Duchenne muscular dystrophy.
Clinically meaningful improvement from 24-week treatment period was maintained for 24 weeks after drisapersen administration ceased Chicago, IL, March 17, 2014 (GLOBE NEWSWIRE) — Prosensa Holding […]
CureDuchenne will host our annual Champions to CureDuchenne Newport Beach Gala on Saturday, March 29 at the Balboa Bay Club & Resort. The event will celebrate CureDuchenne’s 10 years of […]
Ì¢âÂÛÏ CureDuchenne, a nonprofit that raises awareness and funds research to find a cure for Duchenne muscular dystrophy, announced today that Chef Jamie Gwen will create a special menu for the annual Champions to CureDuchenne Newport Beach Gala on Saturday, March 29 at the Balboa Bay Club & Resort. Proceeds of this event will fund promising research to find a cure for Duchenne, a progressive muscle-wasting disease that impacts 1 in 3,500 boys.
CureDuchenne, a nonprofit that raises awareness and funds research to find a cure for Duchenne muscular dystrophy, will host its annual Champions to CureDuchenne Newport Beach Gala on Saturday, March 29 at the Balboa Bay Club & Resort. The event will celebrate CureDuchenneÌ¢âÂã¢s 10 years of successfully advancing Duchenne research. At the event, CureDuchenne will honor a nationally recognized former tax attorney and business executive, Doug Freeman, who played an integral role in establishing CureDuchenneÌ¢âÂã¢s successful venture philanthropy model.
Leiden, February 18th , 2014 Dear Patient Group Representative, We hope this note finds you well. When we last communicated, we announced that Prosensa had regained all rights to drisapersen […]
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today announced new pulmonary function data through Week 120 from Study 202, a Phase IIb open-label extension study of eteplirsen in patients with Duchenne muscular dystrophy (DMD). Results through more than two years of treatment showed stable pulmonary function in the Intent-to-Treat (ITT) study population (N=12). These data are consistent with previously reported 120-week clinical data showing a general stabilization of walking ability in eteplirsen-treated patients evaluable on the 6-minute walk test (6MWT).
Sarah Burgess, singer-songwriter and contestant on the sixth season of American Idol, launches a behind-the-scenes video for her new song Ì¢âÂÒRun AwayÌ¢âÂÌ_ today to benefit CureDuchenne, a national nonprofit organization that raises awareness and funds research to find a cure for Duchenne muscular dystrophy.
Dr. Giles Campion, Prosensa’s Chief Medical Officer (https://www.prosensa.eu/) presented an overview of the latest drisapersen results in this morning’s patient webinar. An analysis of the Phase III data suggests that […]
